Pharma body refutes US study findings on India-made drugs

THE INDIAN PHARMACEUTICAL Alliance (IPA) has dismissed the findings of a recent study published by Ohio State University that claims that generic drugs produced in India have 54% more severe adverse outcomes than US-made drugs.

- MANU KAUSHIK

The pharma body has said the US Food and Drug Administration (USFDA) conducts strict inspections for manufacturing sites within the US and other markets such as India.

"The FDA has established an office in India looking into the number of Indian manufacturers qualified to supply generic medicines to the US. FDA has also implemented a foreign unannounced inspection pilot programme to increase surveillance inspections of foreign drug facilities. Since March 2022, several unannounced and short-term notice inspections have been conducted in India," IPA said in a statement.